volume 2, issue 8, PS505 2007
DOI: 10.1097/01.jto.0000283502.34634.45
View full text
|
|
Share

Abstract: Small molecule inhibitors of epidermal growth factor receptor (EGFR), gefitinib and erlotinib, have been extensively studied in Non-small cell lung cancer (NSCLC) patients. The discovery of molecular biomarkers that identify the subgroups of NSCLC patients benefiting from EGFR tyrosine kinase inhibitor (TKI) has become an important area of investigation. Recently studies, which suggested that epithelial-mesenchymal transition (EMT) in tumors decreases cellular requirements for EGFR signaling pathway, provided …

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals